Korean J Urol.  1988 Oct;29(5):706-712.

The Use of Bacillus Calmette-Guerin in the Therapy for Superficial Bladder Carcinoma

• Kim BW
• Chang SK
• Cho DT

Abstract

Intravesical instillation of Tice Chicago strain BCG(120mg) was given to 21 patients with biopsy proved superficial transitional cell carcinoma. A short course therapy group consisting of 6 or 8 weekly instillation was followed by monthly cystoscopic examination and cytology in 13 patients. Maintenance therapy consisting of twice dose of BCG and monthly 4 courses booster instillation were given to 15 patients considering of high risk group. We evaluated PPD skin test & Multi-test responsiveness in both cancer group and 22 control group. Of 21 cancer patients whose preinstillation PPD negativeness was 75% and convert rate from negative to positive was 75% and in control group their PPD negative ratio is also 70%(9 cases). Side effects were minor and self limiting in the majority of patients without using antituberculors regimen. Although our limited experience, BCG immunotherapy may be also the current treatment of choice for patients with superficial bladder cancer and will require further investigation especially in our Korea.

Keyword

BCG; bladder cancer

MeSH Terms

Administration, Intravesical
Bacillus*
Biopsy
Carcinoma, Transitional Cell
Humans
Immunotherapy
Korea
Mycobacterium bovis
Skin Tests
Urinary Bladder Neoplasms
Urinary Bladder*